Acorda Therapeutics (ACOR) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
MLV & Co. Starts Acorda Therapeutics, Inc. (ACOR) at Buy
February 12, 2015 8:33 AM ESTMLV & Co. initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Buy rating and a price target of $58.00.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click... More
